Interleukin-10 induces interferon-γ-dependent emergency myelopoiesis.
IFN-γ
IL-10
T cells
emergency myelopoiesis
Journal
Cell reports
ISSN: 2211-1247
Titre abrégé: Cell Rep
Pays: United States
ID NLM: 101573691
Informations de publication
Date de publication:
26 10 2021
26 10 2021
Historique:
received:
18
11
2020
revised:
17
05
2021
accepted:
05
10
2021
entrez:
27
10
2021
pubmed:
28
10
2021
medline:
11
2
2022
Statut:
ppublish
Résumé
In emergency myelopoiesis (EM), expansion of the myeloid progenitor compartment and increased myeloid cell production are observed and often mediated by the pro-inflammatory cytokine interferon gamma (IFN-γ). Interleukin-10 (IL-10) inhibits IFN-γ secretion, but paradoxically, its therapeutic administration to humans causes hematologic changes similar to those observed in EM. In this work, we use different in vivo systems, including a humanized immune system mouse model, to show that IL-10 triggers EM, with a significant expansion of the myeloid progenitor compartment and production of myeloid cells. Hematopoietic progenitors display a prominent IFN-γ transcriptional signature, and we show that IFN-γ mediates IL-10-driven EM. We also find that IL-10, unexpectedly, reprograms CD4 and CD8 T cells toward an activation state that includes IFN-γ production by these T cell subsets in vivo. Therefore, in addition to its established anti-inflammatory properties, IL-10 can induce IFN-γ production and EM, opening additional perspectives for the design of IL-10-based immunotherapies.
Identifiants
pubmed: 34706233
pii: S2211-1247(21)01357-7
doi: 10.1016/j.celrep.2021.109887
pii:
doi:
Substances chimiques
IFNG protein, mouse
0
IL10 protein, mouse
0
Interleukin-10
130068-27-8
Interferon-gamma
82115-62-6
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
109887Informations de copyright
Copyright © 2021 The Author(s). Published by Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of interests Y.L. is currently consulting for GemPharmatech Co.